Introduction
============

Maintenance of adequate brain perfusion is an essential component of post-resuscitation care. Mean arterial pressure (MAP) and PaCO~2~are important determinants of brain perfusion; however, no precise guidelines exist for optimal MAP and PaCO~2~targets in comatose post-cardiac arrest (CA) patients.

Methods
=======

Using NIRS, we examined changes in non-invasive cerebral tissue oxygen saturation (SctO~2~) following moderate hyperventilation (HV) and induced hypertension (IH) in comatose CA patients treated with therapeutic hypothermia (TH). A prospective pilot study including comatose patients successfully resuscitated from out-of-hospital CA treated with TH (33°C for 24 hours, using cold saline and surface cooling device), monitored for continuous SctO~2~with the Foresight NIRS system (CAS Medical Systems, Branford, CT, USA). Moderate hyperventilation was induced for approximately 30 minutes by decreasing PaCO~2~from \~40 to \~30 mmHg, at stable MAP. After PaCO~2~normalization, MAP was increased from \~70 to \~90 mmHg by intravenous infusion of norepinephrine, at stable PaCO~2~. Effects of MV and IH on SctO~2~were analyzed with a paired *t*test.

Results
=======

Ten patients (mean age, 69.5; mean time to ROSC, 19 minutes) were studied during the stable TH maintenance phase. Results are summarized in Figure [1](#F1){ref-type="fig"}. MV was associated with a significant reduction of SctO~2~from baseline (75% (73 to 76) to 69% (67.5 to 71.5), *P \<*0.001).

No significant changes in SctO~2~were found after IH (74 (72 to 76) vs. 75 (73 to 75.5), *P*= 0.24).

Conclusion
==========

Moderate HV was associated with significant reduction in cerebral saturation, whilst IH may be detrimental after CA and TH, whilst increasing MAP to supranormal levels with vasopressors does not improve cerebral oxygenation. These data stress the importance of strict control of PaCO~2~following CA and TH to avoid secondary cerebral ischemic insults.

![**Changes in SctO~2~after moderate HV and IH tests (*n =*10 patients)**.](cc12249-1){#F1}
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